Loading...
•
Dec 31, 2024
Bio-Rad Q4 2024 Earnings Report
Bio-Rad reported a revenue decline due to weakness in the Life Science segment, partially offset by growth in Clinical Diagnostics.
Key Takeaways
Bio-Rad's Q4 2024 revenue decreased by 2.00% YoY to $667,500,000, impacted by a decline in the Life Science segment. However, Clinical Diagnostics grew slightly. Operating margin declined due to higher restructuring costs, but cost efficiencies helped maintain profitability.
Revenue declined by 2.00% YoY due to weakness in the Life Science segment.
Clinical Diagnostics saw 0.90% YoY growth, driven by increased demand for quality control and blood typing products.
Operating margin decreased from 15.50% to 13.80% due to increased restructuring costs.
Bio-Rad expects modest revenue growth of 1.50% - 3.50% in 2025, with continued focus on margin expansion.
Bio-Rad
Bio-Rad
Bio-Rad Revenue by Segment
Revenue by Segment
Life Science Revenue
CapyFin.comClinical Diagnostics Revenue
CapyFin.com Forward Guidance
Bio-Rad expects 1.50% - 3.50% revenue growth in 2025, with a non-GAAP operating margin of 13.00% - 13.50%. The company remains focused on its transformation strategy, cost efficiencies, and digital PCR expansion.
Positive Outlook
- Projected revenue growth of 1.50% - 3.50% in 2025.
- Expected non-GAAP operating margin between 13.00% - 13.50%.
- Continued focus on transformation initiatives and cost management.
- Planned acquisition of Stilla Technologies to expand digital PCR capabilities.
- Increased investment in Clinical Diagnostics product innovation.
Challenges Ahead
- Life Science segment remains under pressure due to biotech and biopharma market weakness.
- Restructuring costs may continue to impact operating margins.
- Macroeconomic uncertainties could affect revenue growth.
- Foreign exchange fluctuations may create volatility in financial results.
- Potential delays in regulatory approvals for new products.
Revenue & Expenses
Visualization of income flow from segment revenue to net income